• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., enrolled its last patient in a Phase II, open-label, randomized trial of MM-121, a human monoclonal antibody, in combination with paclitaxel, compared to paclitaxel alone in advanced ovarian cancers.